New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)

Dateline City: KENILWORTH, N.J. Further Analyses on the Long-Term Safety and Efficacy of VYTORIN® from the IMPROVE-IT Study Presented at the European Society of Cardiology (ESC) Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. “IMPROVE-IT presents us with the opportunity to look at cardiovascular outcomes data for patients treated with the combination of simvastatin and ezetimibe (VYTORIN) and allows us to look at the important aspect of long-term safety and efficacy under controlled conditions,” said Dr. Michael A. Blazing, Duke Department of Medicine. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Source Type: news

Related Links:

Conclusion: This study shows that SIM negatively affects the inflammatory and repair phases of the postinjury muscle regeneration. These findings are unique, strengthen the available knowledge on the side effects of SIM, and provide evidence showing that statin therapy is associated with an increased risk of impairment of the regenerative capacity of muscle. PMID: 30519583 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
HIGHER doses of statins could prevent 12,000 heart attacks and strokes a year, a study has found.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Gremese E, DE Lorenzis E, Ferraccioli GF PMID: 30504479 [PubMed - in process]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
CONCLUSION: These data suggest that better absorption and tissue distribution of BPF Phyto formulation represents an innovative approach in supplementation treatments of cardiometabolic disorders. PMID: 30501605 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Measures of hospital quality, statin under- or over-use, Botox for AF, smoking cessation and translating trial evidence to clinical practice are discussed in this week ’ s podcast.theheart.org on Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Publication date: Available online 6 December 2018Source: The Lancet Global HealthAuthor(s): Sanjay Basu, Ryan G Wagner, Ronel Sewpaul, Priscilla Reddy, Justine DaviesSummaryBackgroundCardiovascular diseases and their risk factors—particularly hypertension, dyslipidaemia, and diabetes—have become an increasing concern for middle-income countries. Using newly available, nationally representative data, we assessed how cardiovascular risk factors are distributed across subpopulations within South Africa and identified which cardiovascular treatments should be prioritised.MethodsWe created a demographically represe...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
Condition:   Hypercholesterolemia Interventions:   Combination Product: EZ 10 mg/Ator 10 mg;   Combination Product: EZ 10 mg/Ator 20 mg;   Drug: Atorvastatin;   Drug: Placebo for FDC EZ/Ator;   Drug: Placebo for atorvastatin Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 6 December 2018Source: Pharmacological ResearchAuthor(s): Krzysztof Dyrbus, Mariusz Gasior, Piotr Desperak, Jolanta Nowak, Tadeusz Osadnik, Maciej BanachAbstractDespite well-defined therapeutic low-density lipoprotein cholesterol (LDL-C) target in the highest-risk population, low percentage of patients is administered with intensive lipid-lowering therapy and achieves recommended levels. Therefore, based on the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry data we investigated the characteristics of lipid profile and management of dyslipidemia in acute coronar...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: December 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 12Author(s): Liam R. Brunham, Isabelle Ruel, Sumayah Aljenedil, Jean-Baptiste Rivière, Alexis Baass, Jack V. Tu, G.B. John Mancini, Paolo Raggi, Milan Gupta, Patrick Couture, Glen J. Pearson, Jean Bergeron, Gordon A. Francis, Brian W. McCrindle, Katherine Morrison, Julie St-Pierre, Mélanie Henderson, Robert A. Hegele, Jacques Genest, Jeannette GoguenAbstractFamilial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals world...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Bempedoic acid (BA; ETC-1002) is a new agent that reduces cholesterol synthesis through inhibition of adenosine triphosphate citrate lyase, an enzyme upstream from 3-hydroxy-3-methylglutaryl-coenzyme A. In animal models, BA also influences fatty acid synthesis, but in humans, its role is limited primarily to lowering low-density lipoprotein cholesterol (LDL-C). In early clinical trials, BA was well tolerated and without major side effects. Alone or in various combinations with atorvastatin and/or ezetimibe, LDL-C lowering ranged from 17% to 64%. In addition, BA lowers levels of non–high-density lipoprotein cholestero...
Source: Cardiology in Review - Category: Cardiology Tags: New Therapy Update Source Type: research
More News: Cardiology | Cardiovascular | Heart | Merck | Pharmaceuticals | Simvastatin | Statin Therapy | Study | Vytorin | Zetia | Zocor